thalidomide + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a multi-agent combination regimen consisting of six drugs: - Thalidomide, an immunomodulatory agent with anti-angiogenic and anti-inflammatory properties, primarily used in multiple myeloma and certain hematologic malignancies. - Rituximab, a chimeric monoclonal antibody targeting CD20 on B lymphocytes, leading to B-cell depletion; widely used in B-cell non-Hodgkin lymphoma and other autoimmune conditions. - Cyclophosphamide, an alkylating agent that crosslinks DNA to inhibit cell division. - Doxorubicin, an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. - Vincristine, a vinca alkaloid that disrupts microtubule formation during mitosis. - Prednisone, a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects. This specific combination does not have a unique acronym or established brand name but represents the addition of thalidomide to the well-known R-CHOP regimen (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone). The rationale for adding thalidomide is its immunomodulatory effect which may enhance antitumor activity. This type of regimen would be considered investigational or off-label for most indications but could be explored in clinical trials for aggressive lymphomas or other hematologic malignancies[1][2][7].